Postbiotics as potential new therapeutic agents for sepsis

Area of Science:

• Microbiology
• Immunology
• Critical Care Medicine

Background:

• Sepsis is a leading cause of death in critically ill patients, with gut microbiota dysbiosis playing a significant role.
• Sepsis disrupts the gut microbiota, leading to organ dysfunction and increased susceptibility to infection.
• Current therapies like probiotics and fecal microbiota transplantation have uncertain efficacy in sepsis-related gut disruptions.

Purpose of the Study:

• To review the concept of postbiotics and their potential therapeutic applications in sepsis.
• To summarize current knowledge on postbiotics for sepsis treatment.
• To explore postbiotics as an adjunctive therapy for sepsis.

Main Methods:

• Literature review on postbiotics and their mechanisms of action.
• Analysis of the role of gut microbiota in sepsis pathogenesis.
• Evaluation of postbiotic properties including antimicrobial, immunomodulatory, antioxidant, and antiproliferative activities.

Main Results:

• Postbiotics are inactivated microbial cells or components with diverse beneficial activities.
• Microbiota-targeted therapies, including postbiotics, may improve sepsis prognosis by regulating gut metabolites and barrier function.
• Postbiotics may offer advantages over traditional probiotics and prebiotics in managing sepsis.

Conclusions:

• Postbiotics demonstrate potential as an adjunctive therapy for sepsis.
• They may help restore gut microbial balance and improve intestinal barrier integrity.
• Further research is warranted to fully establish the clinical utility of postbiotics in sepsis management.